Aurobindo's fosinopril sodium tabs receives US FDA nod for hypertension
Aurobindo Pharma Limited has announced that the company has received US Food and Drug Administration (US FDA) final approval for fosinopril sodium and hydochlorothiazide tablets USP 10/12.5 mg and 20/12.5 mg.
Fosinopril sodium and hydochlorothiazide tablets USP 10/12.5 mg and 20/12.5 mg is generic equivalent to Monopril HCT tablets 10/12.5 mg and 20/12.5 mg of Bristol Myers Squibb. Fosinopril sodium and hydochlorothiazide tablets are indicated for hypertension and fall under the cardio vascular system (CVS) therapeutics segment. The product will be launched shortly, a company press release said.
Comments